FDA 483 OBSERVATION · #1425 OF 1,918 MOST-CITED
Reporting
FDA cited this observation 9 times across 9 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
How FDA worded it — real examples
The IRB's termination of approval for research was not reported to the investigator.
The IRB's suspension for research was not reported promptly to appropriate institutional officials.
The IRB's suspension for research was not reported to appropriate institutional officials and the Food and Drug Administration.
The IRB's suspension and termination of approval for research was not reported promptly to the Food and Drug Administration.
The IRB's termination of approval for research was not reported to the Food and Drug Administration.
The IRB's suspension for research was not reported promptly to appropriate institutional officials and the Food and Drug Administration.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →